The Peptide Pivot: Why Pharma Is Moving From Masking Disease to Solving It

There is a quiet structural shift happening in pharmaceutical R&D, and it has nothing to do with AI drug discovery or CRISPR gene editing. It is about peptides — short chains of amino acids that sit in the pharmacological sweet spot between small molecules and biologics. And it may be the most important modality transition since monoclonal antibodies reshaped oncology two decades ago.

The global peptide therapeutics market was valued at $140.86 billion in 2025 and is projected to roughly double to $294.58 billion by 2033, according to Grand View Research. Over 80 peptide drugs have FDA approval. More than 150 peptide candidates are in clinical trials, with another 600 to 700 in preclinical development. Eli Lilly committed more than $6 billion to a new peptide manufacturing facility in Alabama. Novo Nordisk is expanding production capacity on a scale unprecedented in the history of drug manufacturing.

But the numbers only tell part of the story. The deeper thesis is about what peptides can do that small molecules cannot — and why that distinction matters for how we treat disease.

The Small Molecule Problem: Masking, Not Solving

Small molecules have been the backbone of pharmaceutical development for a century, and for good reason. They are chemically synthesizable, orally bioavailable, shelf-stable, and inexpensive to manufacture. In 2025, small molecules accounted for 65% of FDA novel drug approvals — up from 56% in 2023 and 2024, according to Drug Discovery Trends.

But small molecules have a fundamental limitation: they are designed to fit into pockets. A small molecule drug works by binding to a specific site on a protein — typically an enzyme's active site or a receptor's ligand-binding domain — and either blocking or activating it. This is excellent for inhibiting a single, well-defined enzymatic activity. It is far less effective when the disease mechanism involves complex protein-protein interactions, multi-receptor signaling networks, or the need to replace a missing biological function rather than block an overactive one.

The result is that many small molecule drugs are, in essence, symptom managers. A statin lowers cholesterol by inhibiting HMG-CoA reductase — but it does not fix the metabolic dysfunction that caused the dyslipidemia. An SSRI blocks serotonin reuptake — but it does not repair whatever neural circuit dysfunction underlies the depression. A beta-blocker reduces blood pressure — but it does not address the cardiovascular remodeling that caused the hypertension.

This is not a criticism of small molecules. It is a recognition of their design constraints. When your tool is a key that fits a lock, every problem looks like a lock. But many diseases are not locks. They are systems — interconnected networks of signaling pathways, feedback loops, and compensatory mechanisms. You cannot solve a systems problem by blocking a single node.

Large Molecules: Solving the Problem, But at a Cost

Biologics — monoclonal antibodies, recombinant proteins, and now cell and gene therapies — take the opposite approach. They are large, complex molecules designed to engage biological systems at the pathway level. An antibody can bind a specific receptor and block an entire signaling cascade. A recombinant protein can replace a missing biological function entirely. A CAR-T cell can reprogram the immune system to recognize and destroy cancer.

Biologics solve problems. But they come with severe practical limitations. They are enormous molecules — typically 150,000 daltons or more — that cannot cross cell membranes, cannot be delivered orally, and require cold-chain manufacturing infrastructure that costs hundreds of millions of dollars to build. They are immunogenic, expensive, and accessible only to patients near specialized treatment centers. A CAR-T therapy that cures cancer in a single infusion but costs $400,000 and requires a three-week hospital stay is a remarkable scientific achievement — and a deeply imperfect medical solution.

The gap between small molecules and biologics has been one of the defining tensions in drug development. Small molecules are practical but superficial. Biologics are profound but impractical. For decades, the industry has been searching for something in between.

Peptides: The Goldilocks Modality

Peptides are short chains of 2 to 50 amino acids. In size, they sit neatly between small molecules (typically under 500 daltons) and biologics (typically over 50,000 daltons). This middle ground gives them a combination of properties that neither small molecules nor biologics can match alone.

Like biologics, peptides can engage complex targets that small molecules cannot reach. Protein-protein interactions — the signaling interfaces that govern most cellular processes — involve large, flat surface areas that are essentially undruggable by small molecules. Peptides, with their larger surface areas and conformational flexibility, can bind these interfaces with high specificity and affinity. This opens up entire classes of targets that have been off-limits to small molecule drug discovery for decades.

Like small molecules, peptides can be chemically synthesized, standardized, and — increasingly — delivered orally. The development of macrocyclic peptides, cyclic structures that resist enzymatic degradation and can cross cell membranes, has pushed peptide drug discovery into "beyond rule of 5" territory that was previously considered undruggable. At the April 2026 Drug Discovery Chemistry conference in Boston, oral and macrocyclic peptide design was one of the most prominent tracks. Companies like Bicycle Therapeutics and Circle Pharmaceuticals are building platforms around macrocyclic peptide scaffolds that combine the target engagement of biologics with the synthetic accessibility of small molecules.

And unlike biologics, peptides have low immunogenicity and can be manufactured at a fraction of the cost. A peptide drug substance can be produced by solid-phase peptide synthesis for tens of dollars per gram. An antibody requires mammalian cell culture facilities that cost hundreds of millions of dollars to build and operate.

GLP-1: Proof of Concept, Not the Ceiling

The GLP-1 revolution — semaglutide, tirzepatide, and the next generation of multi-agonist peptides — has been the commercial proof of concept that put peptides on every pharma company's strategic roadmap. But the significance of GLP-1 drugs goes beyond their commercial success. They demonstrate something fundamental about peptide pharmacology.

Consider what tirzepatide actually does. It is a dual agonist of the GLP-1 and GIP receptors — two distinct signaling pathways that jointly regulate glucose metabolism, appetite, and energy expenditure. By engaging both receptors simultaneously, tirzepatide achieves 20%+ weight loss and meaningful cardiovascular risk reduction — outcomes that no single-target small molecule has ever approached. The next generation — retatrutide, a triple agonist adding glucagon receptor activation — is pushing weight loss toward 25% and showing early signals in liver disease and kidney protection.

This is the peptide thesis in miniature. These drugs do not suppress appetite by blocking a single receptor. They modulate an entire metabolic system by engaging multiple signaling pathways simultaneously, addressing the underlying metabolic dysfunction rather than masking a single symptom. The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in 17,604 patients — not because it lowers blood sugar, but because it re-regulates the metabolic pathways that drive cardiovascular disease.

That is what solving looks like, as opposed to masking.

Beyond GLP-1: The Pipeline Shift

The peptide pipeline is now diversifying well beyond metabolic disease, and this is where the investment thesis gets interesting. According to a 2025 review in ScienceDirect, over 150 peptide candidates are in active clinical trials, with metabolic disease and cancer leading the pipeline. But the expansion into other therapeutic areas is accelerating.

In oncology, peptide-drug conjugates are emerging as a precision delivery platform. Novartis's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) — a PSMA-targeted peptide radioligand that delivers targeted radiation directly to prostate cancer cells — has become a blockbuster and validated the peptide conjugate approach. The peptide acts as a homing device, guiding a cytotoxic payload to tumor cells while sparing healthy tissue. Multiple companies are now developing peptide-drug conjugates that link tumor-selective peptides to chemotherapy payloads, radionuclides, or immune-stimulating agents.

In rare disease, Q1 2026 saw peptide therapy approvals for skeletal disease, rare hypothalamic disorders, and complement-mediated kidney disease. In immunology, clinical data emerged suggesting that metabolic peptide therapies may complement established immune-targeted medicines — raising the possibility that treating underlying metabolic dysfunction could enhance outcomes in diseases historically managed only through immunomodulation.

In neuroscience, oral peptide candidates targeting pathological protein aggregation advanced during the quarter, pointing toward a future where peptides may address the protein-misfolding mechanisms that drive Alzheimer's, Parkinson's, and related disorders — not by masking cognitive decline, but by interfering with the aggregation process at its source.

The Manufacturing Arms Race

The peptide thesis is not just about science. It is about manufacturing capacity, and this is where the investment landscape becomes concrete. Peptide drug manufacturing at commercial scale is fundamentally different from small molecule synthesis or biologics production. It requires specialized facilities for solid-phase peptide synthesis, purification, and formulation — capabilities that are in critically short supply.

Eli Lilly's $6 billion commitment to its Alabama peptide manufacturing facility, announced in late 2025, is the most visible signal of this buildout. Novo Nordisk has been investing billions in expanding its semaglutide and tirzepatide production capacity. WuXi AppTec has established an end-to-end peptide CRDMO platform spanning discovery through commercial manufacturing. PolyPeptide Group and Bachem are scaling capacity aggressively.

The manufacturing bottleneck is real. Current global peptide synthesis capacity is insufficient to meet projected demand, and the companies that control peptide manufacturing infrastructure will hold enormous strategic leverage as the pipeline matures. This is not a software problem that can be solved with more code. It is a physical chemistry problem that requires specialized facilities, trained personnel, and years of construction lead time.

The Investment Framework

For investors evaluating the peptide thesis, the opportunity breaks into three layers.

The first layer is the peptide drug developers themselves — companies with peptide candidates in late-stage clinical trials. These are the highest-risk, highest-reward plays. Replimune, Biohaven, and the GLP-1 developers have shown that a single successful peptide candidate can create enormous value. But the pipeline is crowded, and many candidates will fail.

The second layer is the peptide manufacturing infrastructure — the CRDMOs and CMOs that produce peptide drug substances and drug products. These are the picks-and-shovels plays. WuXi AppTec, Bachem, and PolyPeptide are the dominant players, but smaller specialists are emerging. This layer offers lower risk and more predictable revenue, because every peptide drug that succeeds creates demand for manufacturing capacity regardless of who developed it.

The third layer is the platform technology — companies building the tools for peptide discovery, design, and delivery. AI-driven peptide design platforms, macrocyclic peptide libraries, and oral peptide delivery technologies are all enabling infrastructure that could become acquisition targets as large pharma builds out its peptide capabilities. The strategic collaborations in Q1 2026 — focused on next-generation metabolic medicines, advanced delivery systems, and macrocyclic peptide platforms — suggest that big pharma is already acquiring these capabilities through partnership and licensing rather than building them internally.

The Real Transition

The shift from small molecules to peptides is not just a change in drug modality. It is a change in how we think about disease. Small molecule drug development has historically been a reductionist enterprise: identify a single molecular target, design a molecule that blocks it, and measure a downstream clinical endpoint. Peptide drug development is a systems-level enterprise: identify a biological pathway or network, design a molecule that modulates it, and measure whether the disease itself improves.

The difference between masking a symptom and solving a problem is the difference between inhibiting an enzyme and re-regulating a metabolic system. It is the difference between lowering blood pressure and addressing the cardiovascular remodeling that caused it. It is the difference between suppressing inflammation and treating the immune dysfunction that drives it.

Peptides are not the only modality capable of this. Biologics do it too — at greater cost and complexity. Gene therapies and cell therapies do it more profoundly — at even greater cost and complexity still. But peptides are the first modality that combines systems-level pharmacology with practical, scalable, affordable drug development. They may be the closest thing to a true middle path that the pharmaceutical industry has ever found.

The $140 billion peptide market is not a bubble. It is the leading edge of a structural transition in how we develop drugs — from masking disease to solving it. The companies that understand this shift earliest, and build the capabilities to exploit it, will define the next era of pharmaceutical innovation.

---

Todd Colpron is the Managing Partner of Eliakim Capital, a boutique principal investment and strategic advisory firm focused on life sciences, capital strategy, and long-term value creation. He works with select management teams navigating growth, investor communications, and capital formation, while evaluating opportunities where Eliakim Capital's experience, relationships, and investment perspective can add meaningful value. The firm may also invest its own capital when an opportunity demonstrates strong strategic alignment and investment merit.